Shorter treatment duration a possibility for pulmonary TB
New data analysis of three clinical trials has suggested that a precision medicine approach could allow some pulmonary TB patients to have significantly shorter treatment periods.
Browsing: Respiratory Infection
FDA approves Xofluza™, the first single-dose oral medicine for influenza
Roche has announced the FDA approval of Xofluza™, the first and only single-dose oral medicine approved to treat flu.
Highlights of the WHO Global Tuberculosis Report
On the day of UNGA’s first-ever high-level meeting on tuberculosis we summarize the key points from the WHO 2018 Global Tuberculosis Report and what this meeting could mean for accelerating progress.
ASM Microbe: Influenza treatment delayed by false negative rapid test results, new study suggests
New research indicates that false negative RIAT results could delay antiviral therapy for half of patients admitted to intensive care units.
Could carbon monoxide be used to manage sepsis-related lung injury? – an interview with Bryan Kraft, MD
In this interview, we speak to Dr. Bryan Kraft, an Assistant Professor of Medicine at Duke University, about his research into carbon monoxide as a potential therapy to treat ARDS and the clinical trial for this therapy that is currently underway.
A peek behind the paper – Lucy Somerville on the impact of influenza virus infection in pregnancy
In this interview, take a look behind the scenes of a recent Future Microbiology review on influenza virus infection in pregnancy with author, Lucy Somerville.
New test could rapidly identify viral respiratory infections
Researchers have developed a novel test that can measure the levels of RNA or proteins in human cells to accurately identify viral respiratory infections
Insights into the evolution of the mutational resistome of Pseudomonas aeruginosa in cystic fibrosis
The term resistome was first used to account for the set of primary antibiotic resistance genes that could be eventually transferred to human pathogens, this editorial delves into the evolution of the mutational resistome of Pseudomonas aeruginosa in cystic fibrosis.
Tuberculosis targets – are we making progress fast enough?
The WHO’s most recent global tuberculosis report has stated that the burden of TB is still high, with gaps in diagnosis and growing drug-resistance posing challenges on our way to ending this epidemic.
New study estimates TB mortality rates in children under 5
A new mathematical modelling study has estimated the mortality rates of TB in the pediatric population, producing the first ever estimate for infants under 5 years of age.
